Human Microbiome Market 2019 | Rich Product Pipeline by Players Enterome Bioscience, Yakult Honsha Co., Ltd., DuPont, Metabiomics Corporation, ViThera Pharmaceuticals, Second Genome Inc., AOBiome LLC, Seres Therapeutics, uBiome, Inc., Rebiotix, Inc., Synt

Increasing number of collaboration activities between various players in the market and between different players and research institutes is expected to aid in the expansion and development of novel medicines for variety of diseases. For instance, in 2017, AOBiome secured US$ 30 million investment for advancing clinical research on systemic and topical inflammatory disorders using novel bacterial platform from iCarbonX. It is evident that such efforts are accelerating the research and development of microbiome platform.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/182

Similarly, in 2017, Stanford University School of Medicine and Vedanta Biosciences Inc. entered in research collaboration to focus on food allergies in children and on patients with C. difficile infection or graft-versus-host disease

Growing incidence of disease conditions in which human microbiome product is used. According to data given by Centre for Disease Control and Prevention in October 2017, Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections in the China and Hong Kong, affecting around 36.1 cases/100,000 person in 2014, an annual increase of 26%. According to study published in Clinical Infectious Disease journal in 2015, about 25% to 33% of antibiotic-associated diarrhea and 90% of pseudomembranous enteritis are caused by CDI.

Increasing prevalence of C. Difficile infection (CDI) is a major factor driving human microbiome market growth. In 2010, the American Society for Microbiology, study of CDI over a 13-year period in Quebec, Canada, reported an increase in incidence from 35.6 cases per 100,000 population in 1991 to 156.3 cases per 100,000 population in 2003. According to study published in Clinical Infectious Disease journal in 2015, about 25% to 33% of antibiotic-associated diarrhea and 90% of pseudomembranous enteritis are caused by CDI.

Moreover, introduction of probiotic may induce change in intestinal microbiota and can stabilize microbial communities, which may prevent gut inflammation, propelling growth of the human microbiome market over the forecast period. For instance, in October 2018, BioGaia subsidiary MetaboGen introduced two new strains Faecalibacterium prausnitzii (DSM 32379) and Desulfovibrio piger (DSM 32187) for safety study. These strains are derived from human gut microbiome.

Moreover, increase in need of early detection and diagnostics of cancer is expected to boost demand for human microbiome market. For instance, in August 2014, National Center for Biotechnology Information (NCBI), stated that Colorectal Cancer (CRC) is third most commonly diagnosed malignancy globally which accounts for around half million deaths annually. The abnormality in gut microbiome in CRC, if diagnosed early can exceed survival rate around 90%.

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/182

Major players operating in the global human microbiome market include, Enterome Bioscience, Yakult Honsha Co., Ltd., DuPont, Metabiomics Corporation, ViThera Pharmaceuticals, Second Genome Inc., AOBiome LLC, Seres Therapeutics, uBiome, Inc., Rebiotix, Inc., Synthetic Biologics, Inc., MicroBiome Therapeutics LLC, Vedanta BioSciences, Osel, Inc., and Merck & Co., Inc.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.